Human ApoE4 ELISA Kit

Sample

human cerebrospinal fluid (CSF), plasma, and serum

Species Reactivity

Human

Detection Method

sELISA

Intended Use

FOR RESEARCH USE ONLY. Not for clinical diagnosis use. The ELISA Kit provides a quantitative assay for human ApoE4 proteins.

Contents of Kit

ApoE (pan) Rabbit mAb Coated Microwells, 96 tests, 4°C
ApoE4 Mouse Detection mAb, 1 each, Lyophilized, 4°C
HRP Diluent, 5.5 mL, 4°C
TMB Substrate, 11 mL, 4°C
STOP Solution, 11 mL, 4°C
Sealing Tape, 2 each, 4°C
ELISA Wash Buffer (20×), 25 mL, 4°C
Cell Lysis Buffer (10×), 15 mL, -20°C

Storage

Kit should be stored at 4°C with the exception of 10× Cell Lysis Buffer, which is stored at -20°C (packaged separately).

Performance Characteristics

The Human ApoE4 ELISA Kit detects ApoE4 in Alzheimer's disease (AD) patient cerebrospinal fluid (CSF), plasma, and serum. The absorbance at 450 nm for 3 dilutions of human CSF, plasma, and serum obtained from one AD patient and one normal donor is shown in the figure.

General Description

Apolipoproteins are plasma lipoproteins that function as transporters of lipids and cholesterol in the circulatory system. Chylomicrons are a fundamental class of apolipoproteins containing very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL). Human ApoE has three isoforms: ApoE2, ApoE3, and ApoE4. These three isoforms differ in the combination of cysteine and arginine residues located at positions 130 and 176. The ApoE4 isoform contains arginine at both locations. Research studies have linked ApoE4 function to neuronal plasticity, synaptogenesis, and neurodegenerative diseases. ApoE4 is produced in the liver and brain, although it is widely expressed in other tissues, such as the lung, spleen, and ovary. Investigators have established the ApoE4 allele as a genetic risk factor for Alzheimer' s disease (AD), accounting for 50-60% of the genetic variation in the disease. Research studies indicate that patients expressing ApoE4 have a reduced capacity for synaptic plasticity, an earlier age of onset of AD, and an increase in amyloid-beta (Aβ) deposition. The increase in Aβ suggests a role for ApoE4 in the impairment of amyloid clearance.

Standard Curve